A collaborative ecosystem driving real-world innovation in cancer care
IMAGINE is designed as an open innovation lab, enabling clinicians, mathematicians, AI developers, imaging scientists, engineers, design experts and medtech companies to collaborate on real-world challenges. By working within a hospital environment, the consortium ensures that innovations are informed by real patient needs and can be safely and rapidly translated into practice.
The IMAGINE consortium unites a comprehensive group of partners from across the healthcare innovation ecosystem:
Academic and Research Institutions: UMC Utrecht, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Radboudumc, Catharina Hospital, Eindhoven University of Technology, Utrecht University and its incubator UtrechtInc, and the National Research Institute for Mathematics and Computer Science (CWI).
Industry Partners: Philips, Elekta, KALCIO Healthcare, and Tesla Dynamic Coils.
Educational Institutions: Fontys University of Applied Sciences, University of Applied Sciences Utrecht, and The Hague University of Applied Sciences.
Together, these partners are advancing the development, validation, and clinical implementation of image-guided technologies to improve cancer care and future-proof the healthcare system.
TWA 7 is blocked in this image by the black circle, while the planet glows in orange – credit, NASA, ESA, CSA, Anne-Marie Lagrange (CNRS, UGA), Mahdi Zamani (ESA / Webb)
Since its debut in 2021, the James Webb Space Telescope has dazzled viewers with its infrared images of galaxies, nebulae, stars, and even our own solar system’s planets.
Now, the most expensive telescope ever made has unveiled a new trick—a coronagraph, which allows it to block the light of a star and see what small objects are orbiting it. In this case, it performed the first direct photographing of an exoplanet in human history; probably.
The image found a faint source of infrared light in a disk of debris orbiting TWA 7, a red dwarf star around 111 light years from Earth. With the outstanding chance of the object being a background galaxy at more than 0%, the researchers can’t say for certain it’s a planet, but they suspect very much that it is—around the size of Saturn and sitting at a comfortable 120° Fahrenheit.
Though astronomers have detected well over 5,000 exoplanets so far, each one has been done through indirect methods, such as the “transit method.” The transit method sees an astronomer train a telescope on a star, and monitor for predictable drops in the level of light from the star that would indicate a planet orbiting it. The transit method can also work through measurements of gravity since passing planets’ gravitational fields can cause their host stars to “wobble.”
By contrast, the coronagraph will be much more straight forward, and TWA 7 b will likely be the first of many that the Webb telescope will discover.
One can think of the coronagraph as an on-demand eclipse service. The instrument positions a disk inside the lens of the imaging device to perfectly eliminate the star’s light from entering the sensor within a degree of micrometers. With the pollution of the star’s light gone, small things—in this case an exoplanet—can be seen.
RECENT WORK FROM JAMES WEBB
“Our observations reveal a strong candidate for a planet shaping the structure of the TWA 7 debris disk, and its position is exactly where we expected to find a planet of this mass,” Anne-Marie Lagrange, lead author of the study and an astrophysicist at the French National Center for Scientific Research, said in a statement released by NASA on the discovery.
The source is located in a gap in one of three dust rings that were discovered around TWA 7 by previous ground-based observations. The object’s brightness, color, distance from the star, and position within the ring are consistent with theoretical predictions for a young, cold, Saturn-mass planet that is expected to be sculpting the surrounding debris disk.
These visible rings or gaps are thought to be created by planets that have formed around the star, but such a planet has yet to be directly detected within a debris disk. If TWA 7 b is confirmed to be such, it would mark a major moment in astronomy.
SHARE This Great New Trick From Our Expensive Space Telescope…
The London-based design disruptor teams up with Ceva to power enhanced listening experiences across the Nothing and CMF sub-brand audio product lines, including the newly announced Nothing Headphone (1)
LONDON and ROCKVILLE, Md., July 2, 2025 /PRNewswire/ — In a move that pushes the boundaries of personal audio, Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, and Nothing, the London-based consumer technology company known for its transparent, design-forward smartphones, audio products and wearables that blend style with performance, today announced a new collaboration to bring Ceva’s RealSpace® Spatial Audio Software to Nothing’s upcoming audio lineup, including the newly announced Nothing Headphone (1), which is the company’s highly anticipated first entry into the over-ear style audio device.
Nothing and Ceva collaborated to bring Ceva’s RealSpace Spatial Audio Software to Nothing’s upcoming audio lineup, including the newly announced Nothing Headphone (1), which is the company’s highly anticipated first entry into the over-ear style audio device.
This collaboration, which provides consumers with a more cinematic and intuitive listening experience, marks a significant step in Nothing’s mission to deliver premium, immersive audio to its global user base under the Nothing and CMF brands. By leveraging Ceva’s industry-leading spatial audio technology and premium wireless audio SoCs powered by Ceva Bluetooth IP, Nothing aims to redefine how users engage with music, movies, and games on wireless audio devices.
“Great audio isn’t just heard, it is felt. It is more than just sound, it’s an emotional connection, an immersive experience, and a reflection of personal identity,” said Andrew Freshwater, Head of Smart Product Marketing at Nothing. “With Ceva’s RealSpace technology, we’re delivering an unparalleled audio experience that envelops users in a richer, more lifelike experience that feels like stepping inside the sound.”
Ceva’s RealSpace® Spatial Audio software is designed for low power consumption, efficient compute, and seamless integration into wireless audio devices. It delivers cinematic 3D sound with dynamic head tracking, making it ideal for Nothing’s sleek, design-first approach to consumer tech.
“Nothing is redefining what tech can look and feel like, and together, we’re pushing the boundaries of what it can sound like,” said Chad Lucien, vice president and general manager of the sensor and audio business unit at Ceva. “Our RealSpace technology will ensure Nothing’s audio products deliver a truly immersive and differentiated listening experience.”
About Ceva RealSpace Ceva RealSpace is a complete Spatial Audio software solution combining precise 3D rendering and accurate, low-latency head tracking. RealSpace supports multiple system architectures, giving you the flexibility to render content directly on TWS earbuds, headphones, XR headsets, or speakers for the lowest latency. Or choose to render on mobile phones, gaming systems, or PCs and save BOM costs on the device. RealSpace operates independently of audio codec choices, source vendors, or device ecosystems and pre-integrated on some of the top audio SoCs in the industry. For more information about the Ceva RealSpace, visit https://www.ceva-ip.com/product/ceva-realspace/.
About Nothing Born in London in 2020, Nothing is building a different kind of tech company – one that inspires human creativity by putting people, design, and excitement back at the centre. From award-winning smartphones to audio products that look and sound different, we’re reimagining how technology should make you feel. Built openly and in collaboration with our global community of over 3 million people, our products are more expressive, more personal, and more fun. In just four years, we’ve sold over 10 million devices and surpassed $1 billion in lifetime revenue. Find out more at nothing.tech.
About Ceva, Inc. At Ceva, we are passionate about bringing new levels of innovation to the smart edge. Our wireless communications, sensing and Edge AI technologies are at the heart of some of today’s most advanced smart edge products. From Bluetooth, Wi-Fi, UWB and 5G platform IP for ubiquitous, robust communications, to scalable Edge AI NPU IPs, sensor fusion processors and embedded application software that make devices smarter, we have the broadest portfolio of IP to connect, sense and infer data more reliably and efficiently. We deliver differentiated solutions that combine outstanding performance at ultra-low power within a very small silicon footprint. Our goal is simple – to deliver the silicon and software IP to enable a smarter, safer, and more interconnected world. This philosophy is in practice today, with Ceva powering more than 19 billion of the world’s most innovative smart edge products from AI-infused smartwatches, IoT devices and wearables to autonomous vehicles and 5G mobile networks.
Our headquarters are in Rockville, Maryland with a global customer base supported by operations worldwide. Our employees are among the leading experts in their areas of specialty, consistently solving the most complex design challenges, enabling our customers to bring innovative smart edge products to market.
Ceva: Powering the Smart Edge™
Visit us at www.ceva-ip.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.
Trump shadow hangs over global development talks Financial Times
Aurangzeb calls for equitable global financial reforms and scaled-up development support at FFD4 Conference Ptv.com.pk
UN chief seeks aid surge to check ‘climate chaos’ Dawn
Invest in aid to build peace in troubled world: UN Geo.tv
Sevilla Platform of Action Launched to Scale Country-Led Financing Approaches for Sustainable Development and Climate United Nations Development Programme
Indonesia will look to continue its winning form in the AFC Women’s Asian Cup qualifiers when it takes on Pakistan in its next qualifier on Wednesday.
The Garuda Pertiwi started its campaign with a 1-0 win over Kyrgyzstan and faces Pakistan next, a side that lost 0-8 to Chinese Taipei in its previous match.
When and where will Pakistan vs Indonesia be played?
The AFC Women’s Asian Cup qualifiers will be played at the Indomilk Arena Stadium in Banten, Indonesia.
The match is scheduled to kick off at 8:00 pm local time (6:30 pm IST).
How to watch Pakistan vs Indonesia AFC Women’s Asian Cup qualifier?
The AFC Women’s Asian Cup qualifier, Pakistan vs Indonesia, will be broadcast on Indosiar and can be live streamed on Vidio Sports.
In the previous match, it was Isa Warps who had struck the winner in the 68th minute, and will be an usual suspect to find the goal against Pakistan too.
The qualification round comprises 34 teams divided into eight groups. The winner of each group will advance to the Asian Cup, set to be played in Australia next year.
Jyothi Yarraji, the national record holder in the women’s 100m hurdles with a personal best timing of 12.78s, was last seen in action at the Taiwan Athletics Open last month, where she won the gold medal in her event after clocking 12.99s.
The Indian athlete also clocked 12.96s to win gold at the Asian Athletics Championship in May.
Jyothi Yarraji’s injury also ends her bid to compete at the 2025 World Athletics Championships, which is set to take place from September 13 to 21.
An Asian Games silver medallist, Yarraji had begun her 2025 season with a gold in the 100m hurdles and 200m race in the National Games in February before bagging top spot in the 100m hurdles at the Federation Cup.
She also successfully defended her Asian Championships title in Gumi, the Republic of Korea.
Vitol, a leader in energy and commodities, and Breakwall Capital (“Breakwall”), a credit investment firm that services the energy industry, announced today the formation of Valor Mining Credit Partners, L.P. (“VMP” or the “Partnership”).
VMP will seek to make structured credit investments in mining companies in the Americas. It will primarily target event-driven financing opportunities focused on debt refinancing, acquisition funding, and development capital, providing companies with flexible solutions to accelerate growth and drive shareholder value.
VMP will be managed by Breakwall, which has an established track record of successfully investing credit capital across all aspects of energy and energy-adjacent value chains and of facilitating the growth and improvement of conventional, renewable, and “next generation” energy companies. This is the second energy credit focused partnership between Vitol and Breakwall. Valor Upstream Credit Partners, L.P. (“VCP”), which is focused on North American upstream oil and gas credit investments, has made over $1 billion in commitments since its launch in June 2023.
Christopher Abbate, Jamie Brodsky, and Daniel Flannery, the Managing Partners of Breakwall, stated: “We are thrilled to partner with Vitol on this new investment strategy. The mining of natural resource deposits and raw materials is a critical, capital-intensive business, and a funding gap exists as the lending landscape is challenged by a lack of capital availability from banks and other direct lenders. We see a tremendous opportunity to bridge an unmet need in the marketplace by providing well-structured credit solutions, as we look to deploy innovative capital solutions across all facets of the energy value chain.”
Ben Marshall, Head of the Americas, Vitol, added: “With the launch of VMP we look forward to expanding our investments in the energy and mining sectors, in partnership with Breakwall. Vitol has long been committed to investing in solutions across the energy spectrum, from traditional solutions to renewables, and we are keen to deploy our capital across a range of opportunities.”
Earlier reports blamed several medications including nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), statins, and antihypertensive agents for triggering microscopic colitis. However, a Swedish study of adults aged 65 years or older found that most of these drugs didn’t increase the risk.
METHODOLOGY:
Although medications are viewed as the main modifiable risk factors for microscopic colitis, research has been limited by nonpopulation-based samples, small and selective cohorts, and study designs vulnerable to immortal time, surveillance, and other biases.
Researchers analyzed prescription records, hospitalizations, medical diagnoses, and gut biopsy findings of more than 2.8 million Swedish individuals aged 65 years or older to determine whether any of the previously implicated medications increased the risk for microscopic colitis.
Target trials — one for each medication — were emulated by including only those without a history of inflammatory bowel disease or microscopic colitis, at least one healthcare encounter in the previous year, no use of a drug from the same class in the prior 180 days, and no known contraindications; the effect of initiating each medication with either not starting it or selecting an alternative therapy was compared.
The primary outcome was biopsy-verified microscopic colitis, with researchers estimating 12- and 24-month cumulative incidences for the risk for microscopic colitis.
TAKEAWAY:
Both 12- and 24-month cumulative incidences for the risk for microscopic colitis were < 0.5% under all treatment strategies.
Estimated risk differences at 12 months and 24 months were close to null for the initiation of antihypertensive medications vs calcium channel blockers, initiation of NSAIDs vs noninitiation, initiation of PPIs vs noninitiation, and initiation of statins vs noninitiation.
However, the initiation of SSRIs vs mirtazapine showed an estimated 12-month risk difference of 0.04% (95% CI, 0.03-0.05); similar results were observed for the estimated 24-month risk difference.
The use of NSAIDs, PPIs, and SSRIs was tied to more colonoscopy exams with normal biopsy results, suggesting that the apparent rise in microscopic colitis after starting an SSRI may have reflected unmeasured bias from ongoing differences in medical care.
IN PRACTICE:
“Our study demonstrated that, contrary to the previous belief, it’s unlikely that medications are the primary triggers for microscopic colitis,” the lead author commented in a press release. “Clinicians should carefully balance the intended benefits of these medication classes against the very low likelihood of a causal relationship with MC [microscopic colitis],” the authors concluded.
SOURCE:
This study was led by Hamed Khalili, MD, MPH, Gastroenterology Unit, Department of Medicine, Massachusetts General Hospital in Boston. It was published online in the Annals of Internal Medicine.
LIMITATIONS:
The Swedish registries do not capture primary care visits, so any symptoms or diagnoses recorded there that might have prompted a colonoscopy went unmeasured. Incomplete colonoscopy records may have obscured why participants actually underwent the procedure. Furthermore, the absence of data on smoking status, body weight, laboratory results, and contraindications could have biased the findings.
DISCLOSURES:
This study was funded in part by the National Institutes of Health, the Swedish Research Council, and the Eric and Wendy Schmidt Center at the Broad Institute of MIT and Harvard. Some authors declared receiving consulting fees, serving on advisory boards, receiving financial support, and other ties with certain pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Formula 1 returns to Silverstone this weekend for the British Grand Prix – and tyre suppliers Pirelli have confirmed the compounds that will be in play.
This year Pirelli have gone one step softer in their range, bringing the C2 as the hard tyre, the C3 as the medium and the C4 as the soft.
Drivers will get two sets of the hard tyre (marked white), three sets of the medium tyre (marked yellow), and eight sets of the soft tyre (marked red), as well as access to the green intermediate tyre and the blue full wets, should they be required.
An extra set of softs is reserved for those who reach Q3 in Qualifying, while all drivers must use at least two different slick compounds during the race, providing the track is dry.
On the decision to bring a range that is one step softer than at last year’s British Grand Prix, Pirelli’s weekend preview says: “The aim, shared with the FIA, F1 and the teams, is to create a wider range of strategy options for the race.
“In 2024, when the C3 was the soft, it was used by just a few drivers in the closing stages of the race following the rain. This year, as the medium, it is bound to play an important role, probably in several phases of the race.
“For those aiming for a one-stop race, the stints will have to be managed very carefully, while accepting a longer total race time. Also a consideration in this equation is the fact that the time taken for a tyre change is not very long (around 20.5 seconds) and while challenging, overtaking is possible.”
In terms of the conditions that can be expected at Silverstone, the tyre manufacturer adds: “The circuit is in almost year-round use with four and two-wheeled racing categories and so it provides good grip right from Friday’s first free practice session, aided by the fact the surface is rated medium-low in terms of abrasiveness.
“Despite taking place at the height of summer, the English weather can often be unpredictable with very changeable temperatures and wind and rain suddenly putting in an appearance, turning the tables during the race, as was the case last year.”
For more information about Pirelli’s F1 tyres, visit pirelli.com.
